Track topics on Twitter Track topics that are important to you
Axovant expects to initiate a study of AXO-Lenti-PD in patients with advanced Parkinson's disease by the end of 2018
Original Article: Axovant Sciences ‘emphasizes reboot’ with gene therapy, says OppenheimerNEXT ARTICLE
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...